Related Experiment Videos

Profibrinolytic activities of chemically modified heparins with very low anticoagulant activities

R Porta1, R Pescador, R Niada

  • 1Crinos Biological Laboratories, Como, Italy.

Thrombosis Research
|March 1, 1989
PubMed

Many evidences indicate that heparin is an activator of fibrinolysis, but the most important side effect of heparin is bleeding which is a problem particularly in the high risk patient. Here we describe how chemical modifications, associated with separation techniques, can sharply reduce the anticoagulant activities of a heparin while its ability to stimulate fibrinolysis is retained.

Related Concept Videos